Targeted Biologic Therapy and Recurrent Ovarian Cancer
Links shared publicly online about this topic
Medical News: ASCO: Biologic Agent Reduces Ovarian Cancer Relapse Risk - in Meeting Coverage, ASCO from MedPage Today
medpagetoday.com — “CHICAGO -- Maintenance therapy with a targeted agent significantly reduced the risk of relapse in women with advanced ovarian and related cancers, a researcher said here.” View full resource at medpagetoday.com
Most Recently Shared on June 6, 2010 at 9:53 pm By:
ASCO: Biologic Agent Reduces Ovarian Cancer Relapse Risk http://bit.ly/az4x68
2010 ASCO: Biologic Agent Reduces Ovarian Cancer Relapse Risk - in Meeting Coverage, ASCO from MedPage Today Video
vodpod.com — “Maintenance therapy with a targeted agent significantly reduced the risk of relapse in women with advanced ovarian and related cancers, a researcher said here. Maintenance therapy with bevacizumab (Avastin) after standard chemotherapy decreased the risk of progression by 28% compared with chemo alone, according to Robert Burger, MD, of Fox Chase Cancer Center in Philadelphia. The approach should now be considered "one standard option" for women with advanced epithelial ovarian, primary” View full resource at vodpod.com
Most Recently Shared on June 6, 2010 at 10:58 pm By:
Paul Cacciatore Patient Advocate
Maintenance therapy with a targeted agent significantly reduced the risk of relapse in women with advanced ovarian and… http://bit.ly/dmsYS9
Double-therapy Approach Effectively Inhibited Brain Cancer Recurrence
medicalnewstoday.com — “Researchers from the University of Massachusetts Medical School have identified a novel approach of combining chemotherapy with a targeted therapy to decrease the recurrence of glioblastoma multif” View full resource at medicalnewstoday.com
Most Recently Shared on August 25, 2010 at 4:00 pm By:
Double-therapy Approach Effectively Inhibited Brain Cancer Recurrence http://mnt.to/3HPJ #biology
Researchers Sequence Complete Genome Of Brain Cancer Cell Line
medicalnewstoday.com — “Cancer researchers at UCLA's Jonsson Comprehensive Cancer Center have performed the complete sequencing of the much-studied brain cancer cell line, U87, a discovery that may lead to ta” View full resource at medicalnewstoday.com
Most Recently Shared on February 2, 2010 at 12:07 pm By:
Researchers Sequence Complete Genome Of Brain Cancer Cell Line Cancer researchers at UCLA's Jonsson Comprehensive Can.. http://bit.ly/auTotw
Proteomics Study Reveals A Protein That, When Suppressed, Makes Cancers More Susceptible To Chemotherapy
medicalnewstoday.com — “Taxanes, a group of cancer drugs that includes paclitaxel (taxol®) and docetaxel (taxotere®), have become front-line therapy for a variety of metastatic cancers. but as with many chemother” View full resource at medicalnewstoday.com
Most Recently Shared on January 28, 2010 at 1:14 pm By:
Proteomics Study Reveals A Protein That, When Suppressed, Makes Cancers More Susceptible To Chemotherapy http://mnt.to/3wRc #cancer
Positive data from Æterna Zentaris' Phase 2 targeted cytotoxic peptide conjugate study
news-medical.net — “Æterna Zentaris Inc., a global biopharmaceutical company focused on endocrine therapy and oncology, today announced positive efficacy data from a Phase 2 study with its targeted cytotoxic peptide conjugate, AEZS-108 (formerly AN-152), in patients with advanced or recurrent endometrial cancer.” View full resource at news-medical.net
Most Recently Shared on November 24, 2009 at 6:15 pm By:
News-Medical.Net Health News and Oncology
Oncology News: Positive data from Æterna Zentaris' Phase 2 targeted cytotoxic peptide conjugate study: Æterna Zen... http://bit.ly/4u0KLK
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Featuring the top 3 experts for this topic
-
FightCancer
Cancer news feed, formerly part of a blog. RSS suggestions welcome.
-
Paul Cacciatore
Founder of Libby's H*O*P*E* (*Helping *Ovarian Cancer Survivors *Persevere Through *Education)
-
MNT Biology News
The latest biology news published daily. Articles from research centers, universities and prestigious journals.
Advertisement
